Curing Infectious Diseases
Sept.,2013
Our First Target is Dengue Fever
1
400 Million Dengue Infections Annually
2CDC-HeathMap Collaboration, http://www.healthmap.org/dengue/
index.php
We Have A Cure For Dengue
3
Control Neutralizing
Serum
A
Control
Peptide 57
B
Control
Peptide ETX-101
C
>99%
Inhibition
ETX-101 Mechanism of Action
4
Issued, Filed or Pending Patents
5
Dengue Products In Development
6
Our Expert Team
7
Robert F. Garry, Ph.D.
Inventor – 30 Yrs
Chief Science Officer
Elizabeth Moore, RPh
30 Yrs Experience
Go...
Dengue Therapeutic Development Plan
8
Preclinical
Preparation
Effectiveness
Non-Human
Primates
Pre-IND
Meeting
Safety/Toxi...
Market Potential
9
$63 Per Dose
$0
$500
$1,000
$1,500
$2,000
Year 1 Year 2 Year 3 Year 4 Year 5
$1.69
Billion
40%
40%
40%
...
Monetization/Exit Strategies
10
Dengue Is Just The Beginning
11
West Nile Virus Hepatitis C
30M Annual Infections 170M Annual Infections
200M Additional D...
Thank You
I Trust That I Have Thoroughly Convinced You That
Ennaid Has The Solution, The Plan & The Team To
Develop Cures ...
Upcoming SlideShare
Loading in …5
×

The corporate presentation ennaid therapeutics

1,063 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,063
On SlideShare
0
From Embeds
0
Number of Embeds
433
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The corporate presentation ennaid therapeutics

  1. 1. Curing Infectious Diseases Sept.,2013
  2. 2. Our First Target is Dengue Fever 1
  3. 3. 400 Million Dengue Infections Annually 2CDC-HeathMap Collaboration, http://www.healthmap.org/dengue/ index.php
  4. 4. We Have A Cure For Dengue 3 Control Neutralizing Serum A Control Peptide 57 B Control Peptide ETX-101 C >99% Inhibition
  5. 5. ETX-101 Mechanism of Action 4
  6. 6. Issued, Filed or Pending Patents 5
  7. 7. Dengue Products In Development 6
  8. 8. Our Expert Team 7 Robert F. Garry, Ph.D. Inventor – 30 Yrs Chief Science Officer Elizabeth Moore, RPh 30 Yrs Experience Gov’t/Industry Regulatory Affairs Darnisha Harrison Microbiologist/Bus. Dev Licensing – 19yrs President & CEO Scott Michael, Ph.D. Co-inventor – 15 Yrs Scientific Advisor SUPPORT TEAM Adrian Barfied 23 Yrs Pharma Entrepreneur Romeo Ibrahim 20 Yrs Process Scientist Thandeka Myeni, MD 14 Yrs Medical Advisor George Davis 20 Yrs Corporate Affairs TIBA Oncology P4 Healthcare
  9. 9. Dengue Therapeutic Development Plan 8 Preclinical Preparation Effectiveness Non-Human Primates Pre-IND Meeting Safety/Toxicity Non-Human Primates IND Submission Phase I/IIa Clinical Trial Phase I/IIa Data Retrieval & Publishing July 2013 Jan 2014 May 2014 Mar 2015 July 2015 May 2016 Oct 2016 $35K $3.7M $265K $3.75M $250K $11M $1M $4,000,000 $4,000,000 $12,000,000
  10. 10. Market Potential 9 $63 Per Dose $0 $500 $1,000 $1,500 $2,000 Year 1 Year 2 Year 3 Year 4 Year 5 $1.69 Billion 40% 40% 40% 40% 40% Economic Savings Revenue In Millions
  11. 11. Monetization/Exit Strategies 10
  12. 12. Dengue Is Just The Beginning 11 West Nile Virus Hepatitis C 30M Annual Infections 170M Annual Infections 200M Additional Doses
  13. 13. Thank You I Trust That I Have Thoroughly Convinced You That Ennaid Has The Solution, The Plan & The Team To Develop Cures For All Four Strains Of Dengue Virus, Followed by Hepatitis C Virus & West Nile Virus.

×